CANbridge Life Sciences, an emerging biopharmaceutical company focusing on developing and commercializing life changing Western drug candidates to address seriously unmet medical needs of Chinese and Asians, has been certified as an International Science and Technology Cooperation Base for Frontier Oncology Diagnosis and Treatment.
Beijing Science and Technology International Cooperation Base is a highly regarded program sponsored and implemented by the Beijing Municipal Science and Technology commission to promote innovation through international collaboration. The program gained increasing influence and momentum for encouraging and rewarding Beijing-based technology companies and academic institutions that provided leadership in drawing global resources to advance innovations. The certification is a major recognition of CANbridge’s innovative business model and would allow the company to tap into major government backed funding and resources in the future.
For more please contact email@example.com.
CANbridge Life Sciences, Ltd. is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.
Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions.
CANbridge is privately-held and headquartered in Beijing, China. For more on CANbridge Life Sciences Ltd., please go to www.canbridgepharma.com.